Skip to main content

RecBio Raises $227 Million for Novel Genetically Engineered Vaccines

RecBio, a Taizhou company that makes genetically engineered biotech vaccines for major diseases, completed a $227 million Series B round. Founded in 2012, the company is developing recombinant vaccines for human papillomavirus (HPV), zoster, tuberculosis and COVID. RecBio will use the proceeds to build a production base and to conduct clinic tests of its 9-valent HPV vaccine and recombinant COVID vaccine. The funding was led by Legend Capital and Lyfe Capital. More details.... Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.